AbbVie Provides 2024 Adjusted Diluted EPS Guidance Of $11.05-$11.25; Includes $0.32/Share Dilutive Impact Related to ImmunoGen And Cerevel Therapeutics Acquisitions, Compared To Consensus Of $11.29
Portfolio Pulse from Benzinga Newsdesk
AbbVie has provided its adjusted diluted EPS guidance for 2024, forecasting $11.05-$11.25. This projection includes a $0.32 per share dilutive impact from the acquisitions of ImmunoGen and Cerevel Therapeutics, which is slightly below the consensus estimate of $11.29.
February 02, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AbbVie's 2024 EPS guidance is slightly below consensus, reflecting dilutive impacts from ImmunoGen and Cerevel Therapeutics acquisitions.
The guidance provided by AbbVie is slightly below the consensus estimates, which could lead to negative investor sentiment in the short term. The dilutive impact of the acquisitions of ImmunoGen and Cerevel Therapeutics is explicitly mentioned as a contributing factor to the lower guidance, indicating a direct impact on AbbVie's financial outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100